<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SENSORCAINE MPF- bupivacaine hydrochloride injection, solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<h1>Sensorcaine MPF Spinal Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c879ce0f-3e83-4f42-9f7e-9704d69a5d84"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">Bupivacaine HCl 0.75% in                                     Dextrose 8.25% Injection    </span></span></p>
<p><span class="Bold"><span class="Emphasis">      Sterile Hyperbaric Solution for Spinal                                     Anesthesia    </span></span></p>
<p>Rx only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="be3f0a8f-b797-4de1-9fd0-005777909114"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:<br>
</h1>
<p class="First">Bupivacaine hydrochloride is 2-Piperidinecarboxamide, 1-butyl-<span class="Italics"><span class="Emphasis">N</span></span>-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate, a white crystalline powder that is freely soluble in 95 percent ethanol, soluble in water, and slightly soluble in chloroform or acetone.  It has the following structural formula:</p>
<br><p><img alt="structure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab7d1ab1-3d58-4562-a3be-c8b2b12e99cf&amp;name=sensorcaine-spinal-figure-1-sen-figure1.jpg"></p>
<p>Dextrose is D-glucopyranose monohydrate and has the following structural formula:</p>
<br><p><img alt="structure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab7d1ab1-3d58-4562-a3be-c8b2b12e99cf&amp;name=sensorcaine-spinal-figure-2-sen-figure2.jpg"></p>
<p>Sensorcaine<span class="Sup">®</span>-MPF Spinal Injection is available in sterile hyperbaric solution for subarachnoid injection (spinal block).</p>
<p>Bupivacaine hydrochloride is related chemically and pharmacologically to the aminoacyl local anesthetics.  It is a homologue of mepivacaine and is chemically related to lidocaine.  All three of these anesthetics contain an amide linkage between the aromatic nucleus and the amino or piperidine group.  They differ in this respect from the procaine-type local anesthetics, which have an ester linkage.</p>
<p>Each mL of Sensorcaine-MPF Spinal Injection contains 7.5 mg bupivacaine hydrochloride (anhydrous) and 82.5 mg dextrose (anhydrous).  The pH of this solution is adjusted to between 4.0 and 6.5 with sodium hydroxide or hydrochloric acid.</p>
<p>The specific gravity of Sensorcaine-MPF Spinal Injection is between 1.030 and 1.035 at 25°C and 1.03 at 37°C.</p>
<p>Sensorcaine-MPF Spinal Injection does not contain any preservatives.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="d28951e8-1dbc-47a5-98cc-e5116a9eed74"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Local anesthetics block the generation and the conduction of                             nerve impulses, presumably by increasing the threshold for electrical                             excitation in the nerve, by slowing the propagation of the nerve                             impulse, and by reducing the rate of rise of the action potential.  In                             general, the progression of anesthesia is related to the diameter,                             myelination, and conduction velocity of affected nerve fibers.                              Clinically, the order of loss of nerve function is as follows:                             (1) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, (2) temperature, (3) touch, (4) proprioception, and (5)                             skeletal muscle tone.</p>
<p>Systemic absorption of local anesthetics produces effects on the                             cardiovascular and central nervous systems (CNS).  At blood                             concentrations achieved with normal therapeutic doses, changes in                             cardiac conduction, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, refractoriness, contractility, and                             peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> are minimal.  However, toxic                             blood concentrations depress cardiac conduction and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, which                             may lead to <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, and cardiac                             arrest, sometimes resulting in fatalities.  In addition,                             myocardial contractility is depressed and peripheral vasodilation                             occurs, leading to decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and arterial blood pressure.                              Recent clinical reports and animal research suggest that these                             cardiovascular changes are more likely to occur after unintended direct                             intravascular injection of bupivacaine.  Therefore, when                             epidural anesthesia with bupivacaine is considered, incremental dosing                             is necessary.</p>
<p>Following systemic absorption, local anesthetics can produce                             central nervous system stimulation, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or both.                              Apparent central stimulation is manifested as <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>,                             <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, progressing to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, followed by                             <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> progressing ultimately to <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.                              However, the local anesthetics have a primary depressant                             effect on the medulla and on higher centers. The depressed                             stage may occur without a prior excited stage.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="b7d14ff6-be83-4a32-bb3b-14da15b96926"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The rate of systemic absorption of local anesthetics is                                     dependent upon the total dose and concentration of drug                                     administered, the route of administration, the vascularity of                                     the administration site, and the presence or absence of                                     epinephrine in the anesthetic solution.  A dilute concentration                                     of epinephrine (1:200,000 or 5 mcg/mL) usually reduces the rate                                     of absorption and peak plasma concentration of bupivacaine,                                     permitting the use of moderately larger total doses and                                     sometimes prolonging the duration of action.</p>
<p>The onset of action with Sensorcaine is rapid and                                     anesthesia is long lasting.  The duration of anesthesia                                     is significantly longer with Sensorcaine than with any other                                     commonly used local anesthetic.  It has also been noted                                     that there is a period of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> that persists after the                                     return of sensation, during which time the need for strong                                     analgesics is reduced.</p>
<p>The onset of sensory blockade following spinal block with                                     Sensorcaine-MPF Spinal Injection is very rapid (within one                                     minute); maximum motor blockade and maximum dermatome level are                                     achieved within 15 minutes in most cases.  Duration of                                     sensory blockade (time to return of complete sensation in the                                     operative site or regression of two dermatomes) following a 12                                     mg dose averages 2 hours with or without 0.2 mg epinephrine.                                      The time to return of complete motor ability with 12                                     mg Sensorcaine-MPF Spinal averages 3½ hours without the                                     addition of epinephrine and 4½ hours if 0.2 mg                                     epinephrine is added.  When compared to equal milligram                                     doses of hyperbaric tetracaine, the duration of sensory blockade                                     was the same but the time to complete motor recovery was                                     significantly longer for tetracaine.  Addition of 0.2                                     mg epinephrine significantly prolongs the motor blockade and                                     time to first postoperative narcotic with Sensorcaine-MPF Spinal                                     Injection.</p>
<p>Local anesthetics appear to cross the placenta by passive                                     diffusion.  The rate and degree of diffusion is                                     governed by (1) the degree of plasma protein binding, (2) the                                     degree of ionization, and (3) the degree of lipid solubility.                                      Fetal/maternal ratios of local anesthetics appear to                                     be inversely related to the degree of plasma protein binding,                                     because only the free, unbound drug is available for placental                                     transfer.  Sensorcaine with a high protein binding                                     capacity (95%) has a low fetal/maternal ratio (0.2 to                                     0.4).  The extent of placental transfer is also                                     determined by the degree of ionization and lipid solubility of                                     the drug.  Lipid soluble, nonionized drugs readily                                     enter the fetal blood from the maternal circulation.</p>
<p>Depending upon the route of administration, local                                     anesthetics are distributed to some extent to all body tissues,                                     with high concentrations found in highly perfused organs such as                                     the liver, lungs, heart, and brain.</p>
<p>Pharmacokinetic studies on the plasma profiles of                                     Sensorcaine after direct intravenous injection suggest a                                     three-compartment open model.  The first compartment is                                     represented by the rapid intravascular distribution of the drug.                                      The second compartment represents the equilibration of                                     the drug throughout the highly perfused organs such as the                                     brain, myocardium, lungs, kidneys and liver.  The third                                     compartment represents an equilibration of the drug with poorly                                     perfused tissues, such as muscle and fat.  The                                     elimination of drug from tissue distribution depends largely                                     upon the ability of binding sites in the circulation to carry it                                     to the liver where it is metabolized.</p>
<p>Various pharmacokinetic parameters of the local                                     anesthetics can be significantly altered by the presence of                                     hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, addition of epinephrine, factors                                     affecting urinary pH, renal blood flow, the route of drug                                     administration, and the age of the patient.  The                                     half-life of bupivacaine in adults is 2.7 hours and in neonates                                     8.1 hours.  In clinical studies, elderly patients exhibited a                                     greater spread and higher maximal level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> than                                     younger patients.  Elderly patients also reached the                                     maximal level of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> more rapidly than younger patients,                                     and exhibited a faster onset of motor blockade.  The                                     total plasma clearance was decreased and the terminal half-life                                     was lengthened in these patients.</p>
<p>Amide-type local anesthetics such as Sensorcaine are                                     metabolized primarily in the liver via conjugation with                                     glucuronic acid.  Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>,                                     especially those with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, may be more                                     susceptible to the potential toxicities of the amide-type local                                     anesthetics.  Pipecoloxylidine is the major metabolite                                     of bupivacaine.</p>
<p>The kidney is the main excretory organ for most local                                     anesthetics and their metabolites.  Urinary excretion                                     is affected by urinary perfusion and factors affecting urinary                                     pH.  Only 6% of bupivacaine is excreted                                     unchanged in the urine.</p>
<p>When administered in recommended doses and                                     concentrations, Sensorcaine does not ordinarily produce                                     irritation or tissue damage and does not cause                                     <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ec55a6e9-c65e-48db-acba-8ef680de99c5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Sensorcaine-MPF Spinal Injection is indicated for the production of subarachnoid block (spinal anesthesia).</p>
<p>Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of spinal anesthesia.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="bf611ddf-9e21-4948-a13c-6b958602f5ef"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Sensorcaine-MPF Spinal Injection is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it or to any local anesthetic agent of the amide type.</p>
<p>The following conditions preclude the use of spinal anesthesia:</p>
<ol>
<li>Severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, such as <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span>, which severely restrict <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>.</li>
<li>Local <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the site of proposed lumbar puncture.</li>
<li><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ab7133f3-25eb-47e8-97ad-63cfdc5f837b"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES WHICH MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED, AND THEN ONLY AFTER INSURING THE <span class="Bold"><span class="Emphasis">IMMEDIATE </span></span>AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY RESUSCITATIVE EQUIPMENT AND THE PERSONNEL RESOURCES NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also <span class="Bold"><span class="Emphasis"><a href="#b967fccc-216b-4565-be20-e853486c760b">ADVERSE REACTIONS </a></span></span>and <span class="Bold"><span class="Emphasis"><a href="#ae4199aa-7d6d-4bc9-97dc-b4796ed0ea3d">PRECAUTIONS</a></span></span>).  DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">ACIDOSIS</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">CARDIAC ARREST</span>, AND, POSSIBLY, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>.</p>
<p>Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving such infusions.  The majority of reported cases of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have involved the shoulder joint; cases of gleno-humeral <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours.  There is insufficient information to determine whether shorter infusion periods are not associated with these findings.  The time of onset of symptoms, such as <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> and loss of motion can be variable, but may begin as early as the 2nd month after surgery.  Currently, there is no effective treatment for <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span>; patients who experienced <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.</p>
<p>Spinal anesthetics should not be injected during uterine contractions, because spinal fluid current may carry the drug further cephalad than desired.</p>
<p>A free flow of cerebrospinal fluid during the performance of spinal anesthesia is indicative of entry into the subarachnoid space.  However, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> should be performed before the anesthetic solution is injected to confirm entry into the subarachnoid space and to avoid intravascular injection.</p>
<p>Sensorcaine solutions containing epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may occur.  Likewise, solutions of Sensorcaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> may result.</p>
<p>Until further experience is gained in patients younger than 18 years, administration of Sensorcaine in this age group is not recommended.</p>
<p>Mixing or the prior or intercurrent use of any other local anesthetic with Sensorcaine cannot be recommended because of insufficient data on the clinical use of such mixtures.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ae4199aa-7d6d-4bc9-97dc-b4796ed0ea3d"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="d1d9b564-db0c-45ac-95ef-e169b86a34b6"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The safety and effectiveness of spinal anesthetics depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies.  Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use (see <span class="Bold"><span class="Emphasis"><a href="#ab7133f3-25eb-47e8-97ad-63cfdc5f837b">WARNINGS </a></span></span>and <span class="Bold"><span class="Emphasis"><a href="#b967fccc-216b-4565-be20-e853486c760b">ADVERSE REACTIONS</a></span></span>).  The patient should have IV fluids running via an indwelling catheter to assure a functioning intravenous pathway.  The lowest dosage of local anesthetic that results in effective anesthesia should be used. <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">Aspiration</span> for blood should be performed before injection and injection should be made slowly.  Tolerance varies with the status of the patient.  Elderly patients and acutely ill patients may require reduced doses.  Reduced doses may also be indicated in patients with increased intra-abdominal pressure (including obstetrical patients), if otherwise suitable for spinal anesthesia.</p>
<p>There should be careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness after local anesthetic injection.  <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, incoherent speech, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the mouth and lips, metallic taste, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> may be early warning signs of central nervous system toxicity.</p>
<p>Spinal anesthetics should be used with caution in patients with severe disturbances of cardiac rhythm, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.</p>
<p>Sympathetic blockade occurring during spinal anesthesia may result in peripheral vasodilation and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, the extent depending on the number of dermatomes blocked.  Patients over 65 years, particularly those with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, may be at increased risk for experiencing the hypotensive effects of Sensorcaine-MPF Spinal Injection.  Blood pressure should, therefore, be carefully monitored especially in the early phases of anesthesia.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may be controlled by vasoconstrictors in dosages depending on the severity of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and response of treatment.  The level of anesthesia should be carefully monitored because it is not always controllable in spinal techniques.</p>
<p>Because amide-type local anesthetics such as Sensorcaine are metabolized by the liver, these drugs, especially repeat doses, should be used cautiously in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.  Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.  Local anesthetics should also be used with caution in patients with impaired cardiovascular function because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  However, dosage recommendations for spinal anesthesia are much lower than dosage recommendations for other major blocks and most experience regarding hepatic and cardiovascular disease dose-related toxicity is derived from these other major blocks.</p>
<p>Serious dose-related <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur if preparations containing a vasoconstrictor such as epinephrine are employed in patients during or following the administration of potent inhalation agents.  In deciding whether to use these products concurrently in the same patient, the combined action of both agents upon the myocardium, the concentration and volume of vasoconstrictor used, and the time since injection, when applicable, should be taken into account.</p>
<p>Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>.  Because it is not known whether amide-type local anesthetics may trigger this reaction and because the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard protocol for management should be available.  Early unexplained signs of <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> may precede temperature elevation.  Successful outcome is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s) and institution of treatment, including oxygen therapy, indicated supportive measures, and dantrolene.  (Consult dantrolene sodium intravenous package insert before using.)</p>
<p>The following conditions may preclude the use of spinal anesthesia, depending upon the physician’s evaluation of the situation and ability to deal with the complications or complaints which may occur.</p>
<ul>
<li>Preexisting diseases of the central nervous system, such as those attributable to <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span>, <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">poliomyelitis</span>, <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>, or tumor.</li>
<li>Hematological disorders predisposing to coagulopathies or patients on anticoagulant therapy.  <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span> to a blood vessel during the conduct of spinal anesthesia may, in some instances, result in uncontrollable central nervous system <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> or soft tissue <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</li>
<li>Chronic <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span> and preoperative <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</li>
<li>Technical problems (persistent <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, persistent bloody tap).</li>
<li><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> or <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span>.</li>
<li>Extremes of age.</li>
<li><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> or other causes of poor cooperation by the patient.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bfd1e579-9b1c-43ec-b3a6-c6368469738a"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">When appropriate, patients should be informed in advance that they may experience temporary <span class="product-label-link" type="condition" conceptid="4141128" conceptname="Absence of sensation">loss of sensation</span> and motor activity, usually in the lower half of the body, following proper administration of spinal anesthesia.  Also, when appropriate, the physician should discuss other information including adverse reactions in the Sensorcaine-MPF Spinal Injection package insert.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fad2d80b-e3ec-4a32-9c65-04664f17eaaa"></a><a name="section-7.3"></a><p></p>
<h2>Clinically Significant Drug Interactions</h2>
<p class="First">The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.</p>
<p>Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe persistent <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>.</p>
<p>Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a3d77920-62ec-4618-ac99-ea25c513e849"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of bupivacaine hydrochloride have not been conducted.  The mutagenic potential and the effect on fertility of bupivacaine hydrochloride have not been determined.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d24dc6a6-3149-4fe1-83be-55609ca4e62a"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">There are no adequate and well-controlled studies in pregnant women.  Bupivacaine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  </p>
<p>Bupivacaine hydrochloride produced developmental toxicity when administered subcutaneously to pregnant rats and rabbits at clinically relevant doses.  This does not exclude the use of Sensorcaine-MPF Spinal Injection at term for obstetrical anesthesia and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#dac439fc-50a3-41d3-a273-471a3df4833a">Labor and Delivery</a></span></span></span>).</p>
<p>Bupivacaine hydrochloride was administered subcutaneously to rats at doses of 4.4, 13.3, &amp; 40 mg/kg and to rabbits at doses of 1.3, 5.8, &amp; 22.2 mg/kg during the period of organogenesis (implantation to closure of the hard palate).  The high doses are approximately 30-times the daily maximum recommended human dose (MRHD) of 12 mg/day on a mg dose/m<span class="Sup">2</span> body surface area (BSA) basis.  No embryo-fetal effects were observed in rats at the high dose which caused increased maternal lethality.  An increase in embryo-<span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> was observed in rabbits at the high dose in the absence of maternal toxicity with the fetal No Observed Adverse Effect Level being approximately 8-times the MRHD on a BSA basis. </p>
<p>In a rat pre- and post-natal development study (dosing from implantation through weaning) conducted at subcutaneous doses of 4.4, 13.3, &amp; 40 mg/kg decreased pup survival was observed at the high dose.  The high dose is approximately 30-times the daily MRHD of 12 mg/day on a BSA basis.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="dac439fc-50a3-41d3-a273-471a3df4833a"></a><a name="section-7.6"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Spinal anesthesia has a recognized use during labor and delivery.  Bupivacaine hydrochloride, when administered properly, via the epidural route in doses 10 to 12 times the amount used in spinal anesthesia has been used for obstetrical <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and anesthesia without evidence of adverse effects on the fetus.</p>
<p>Maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has resulted from regional anesthesia.  Local anesthetics produce vasodilation by blocking sympathetic nerves.  Elevating the patient’s legs and positioning her on her left side will help prevent decreases in blood pressure.  The fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable.</p>
<p>It is extremely important to avoid aortocaval compression by the gravid uterus during administrations of regional block to parturients.  To do this, the patient must be maintained in the left lateral <span class="product-label-link" type="condition" conceptid="4127794" conceptname="Decubitus">decubitus</span> position or a blanket roll or sandbag may be placed beneath the right hip and the gravid uterus displaced to the left.</p>
<p>Spinal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts.  Spinal anesthesia has also been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function.  The use of obstetrical anesthesia may increase the need for forceps assistance.</p>
<p>The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life.  This has not been reported with bupivacaine.</p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> during use of Sensorcaine Injection 0.75% solution for <span class="Underline"><span class="Emphasis">epidural</span></span> anesthesia in obstetrical patients.  The package insert for Sensorcaine Injection for epidural, nerve block, etc., has a more complete discussion of preparation for, and management of, this problem.  These cases are compatible with systemic toxicity following unintended intravascular injection of the much larger doses recommended for <span class="Underline"><span class="Emphasis">epidural</span></span> anesthesia and have not occurred within the dose range of bupivacaine hydrochloride 0.75% recommended for spinal anesthesia in obstetrics.  The 0.75% concentration of Sensorcaine is therefore not recommended for obstetrical epidural anesthesia. Sensorcaine-MPF Spinal Injection (bupivacaine hydrochloride in dextrose injection, USP) is recommended for spinal anesthesia in obstetrics.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b1c74109-b250-46a9-b19e-88a3182fcad2"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Bupivacaine has been reported to be excreted in human milk suggesting that the nursing infant could be theoretically exposed to a dose of the drug.  Because of the potential for serious adverse reactions in nursing infants from bupivacaine, a decision should be made whether to discontinue nursing or not administer bupivacaine, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b64012cf-c718-434b-a073-919acf2c0fe3"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Until further experience is gained in patients younger than 18 years, administration of Sensorcaine-MPF Spinal Injection in this age group is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b2cc6e7e-e7bf-422e-9ad1-b5186b7f2a27"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Patients over 65 years, particularly those with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, may be at increased risk for developing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> while undergoing spinal anesthesia with Sensorcaine-MPF Spinal Injection (see <span class="Bold"><span class="Emphasis"><a href="#ae4199aa-7d6d-4bc9-97dc-b4796ed0ea3d">PRECAUTIONS</a></span></span>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#d1d9b564-db0c-45ac-95ef-e169b86a34b6">General</a> </span></span></span>and <span class="Bold"><span class="Emphasis"><a href="#b967fccc-216b-4565-be20-e853486c760b">ADVERSE REACTIONS</a><span class="Italics">, <a href="#ef00e244-0216-42d9-83c6-d186bdcb5714">Cardiovascular System</a></span></span></span><span class="Bold"><span class="Emphasis">).</span></span></p>
<p>Elderly patients may require lower doses of Sensorcaine-MPF Spinal Injection (see <span class="Bold"><span class="Emphasis"><a href="#ae4199aa-7d6d-4bc9-97dc-b4796ed0ea3d">PRECAUTIONS</a></span></span>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#d1d9b564-db0c-45ac-95ef-e169b86a34b6">General</a></span></span></span> and <span class="Bold"><span class="Emphasis"><a href="#ead0e7c4-647a-4c73-9817-e8c6e42f07dd">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p>In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients (see <span class="Bold"><span class="Emphasis"><a href="#d28951e8-1dbc-47a5-98cc-e5116a9eed74">CLINICAL PHARMACOLOGY</a></span></span><span class="Bold"><span class="Emphasis">, </span></span><span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#b7d14ff6-be83-4a32-bb3b-14da15b96926">Pharmacokinetics</a></span></span></span>).</p>
<p>This product is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><span class="Emphasis"><a href="#d28951e8-1dbc-47a5-98cc-e5116a9eed74">CLINICAL PHARMACOLOGY</a></span></span><span class="Bold"><span class="Emphasis">, </span></span><span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#b7d14ff6-be83-4a32-bb3b-14da15b96926">Pharmacokinetics</a></span></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b967fccc-216b-4565-be20-e853486c760b"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Reactions to bupivacaine are characteristic of those associated with other amide-type local anesthetics.</p>
<p>The most commonly encountered acute adverse experiences which demand immediate countermeasures following the administration of spinal anesthesia are <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> due to loss of sympathetic tone and <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> or underventilation due to cephalad extension of the motor level of anesthesia.  These may lead to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> if untreated.  In addition, dose-related <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> may result from diminished tolerance, rapid absorption from the injection site, or from unintentional intravascular injection of a local anesthetic solution.  Factors influencing plasma protein binding, such as <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, systemic diseases which alter protein production, or competition of other drugs for protein binding sites, may diminish individual tolerance.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="fcf706d3-e9af-4ce1-a40d-779974c50930"></a><a name="section-8.1"></a><p></p>
<h2>Respiratory System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">Respiratory paralysis</span> or underventilation may be noted as a result of upward extension of the level of spinal anesthesia and may lead to secondary <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxic</span> <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> if untreated.  Preanesthetic medication, intraoperative analgesics and sedatives, as well as surgical manipulation, may contribute to underventilation.  This will usually be noted within minutes of the injection of spinal anesthetic solution, but because of differing maximal onset times, differing intercurrent drug usage and differing surgical manipulation, it may occur at any time during surgery or the immediate recovery period.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ef00e244-0216-42d9-83c6-d186bdcb5714"></a><a name="section-8.2"></a><p></p>
<h2>Cardiovascular System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> due to loss of sympathetic tone is a commonly encountered extension of the clinical pharmacology of spinal anesthesia.  This is more commonly observed in elderly patients, particularly those with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and in patients with shrunken blood volume, shrunken interstitial fluid volume, cephalad spread of the local anesthetic, and/or mechanical obstruction of venous return.  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> are frequently associated with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotensive episodes</span> following the administration of spinal anesthesia.  High doses, or inadvertent intravascular injection, may lead to high plasma levels and related <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium, decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, and possibly, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (see <span class="Bold"><span class="Emphasis"><a href="#ab7133f3-25eb-47e8-97ad-63cfdc5f837b">WARNINGS</a></span></span><span class="Bold"><span class="Emphasis">, </span></span><span class="Bold"><span class="Emphasis"><a href="#ae4199aa-7d6d-4bc9-97dc-b4796ed0ea3d">PRECAUTIONS</a></span></span>, and <span class="Bold"><span class="Emphasis"><a href="#b1d457a7-0cf4-416f-a9f0-ed05fc99c172"> OVERDOSAGE</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="fd4aa728-4aa6-484f-b84e-4733f1989886"></a><a name="section-8.3"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">Respiratory paralysis</span> or underventilation secondary to cephalad spread of the level of spinal anesthesia (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#fcf706d3-e9af-4ce1-a40d-779974c50930">Respiratory System</a></span></span></span>) and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> for the same reason (see <span class="Italics"><span class="Emphasis"><span class="Bold"><a href="#ef00e244-0216-42d9-83c6-d186bdcb5714">Cardiovascular System</a></span></span></span>) are the two most commonly encountered central nervous system-related adverse observations which demand immediate countermeasures.</p>
<p>High doses or inadvertent intravascular injection may lead to high plasma levels and related central nervous system toxicity characterized by <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> and/or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.  <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> may occur, possibly proceeding to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  However, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> may be transient or absent, with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> being the first manifestation of an adverse reaction.  This may quickly be followed by <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a4fd837f-ba89-487c-9663-f464152baccd"></a><a name="section-8.4"></a><p></p>
<h2>Neurologic</h2>
<p class="First">The incidences of adverse <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic reactions</span> associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient.  Many of these effects may be related to local anesthetic techniques, with or without a contribution from the drug.</p>
<p>Neurologic effects following spinal anesthesia may include loss of perineal sensation and sexual function, persistent anesthesia, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> of the lower extremities, and loss of sphincter control all of which may have slow, incomplete, or no recovery; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; high or total spinal block; <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, septic <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>; <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningismus</span>, <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">arachnoiditis</span>; slowing of labor, increased incidence of forceps delivery; <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>; cranial nerve palsies due to traction on nerves from loss of cerebrospinal fluid; and fecal and <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="bb1ebd1b-a1c1-407e-b2a7-4f7f87609fa0"></a><a name="section-8.5"></a><p></p>
<h2>Allergic</h2>
<p class="First">Allergic-type reactions are rare and may occur as a result of sensitivity to the local anesthetic.  These reactions are characterized by signs such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> (including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>), <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, elevated temperature, and, possibly, anaphylactoid-like symptomatology (including severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>).  Cross sensitivity among members of the amide-type local anesthetic group has been reported.  The usefulness of screening for sensitivity has not been definitely established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="c208aef6-5519-45c3-92e8-f53366f88f76"></a><a name="section-8.6"></a><p></p>
<h2>Other</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur during spinal anesthesia.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="b1d457a7-0cf4-416f-a9f0-ed05fc99c172"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use or to underventilation (and perhaps <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>) secondary to upward extension of spinal anesthesia.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> is commonly encountered during the conduct of spinal anesthesia due to relaxation of sympathetic tone, and sometimes, contributory mechanical obstruction of venous return.</p>
<div class="Section" data-sectionCode="34088-5">
<a name="c347fafe-6d21-45ed-af99-1d12ee96e678"></a><a name="section-9.1"></a><p></p>
<h2>Management of Local Anesthetic Emergencies</h2>
<p class="First">The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection.  At the first sign of change, oxygen should be administered.</p>
<p><span class="Italics"><span class="Emphasis">The first step in the management of systemic toxic reactions, as well as underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to a high or total spinal, consists of </span></span><span class="Bold"><span class="Emphasis"><span class="Italics">immediate </span></span></span><span class="Italics"><span class="Emphasis">attention to the establishment and maintenance of a patent airway and effective assisted or controlled ventilation with 100% oxygen with a delivery system capable of permitting immediate positive airway pressure by mask. </span></span> This may prevent <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> if they have not already occurred.</p>
<p>If necessary, use drugs to control the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  A 50 mg to 100 mg bolus IV injection of succinylcholine will paralyze the patient without depressing the central nervous or cardiovascular systems and facilitate ventilation.  A bolus IV dose of 5 mg to 10 mg of diazepam or 50 mg to 100 mg of thiopental will permit ventilation and counteract central nervous system stimulation, but these drugs also depress central nervous system, respiratory and cardiac function, add to postictal <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and may result in <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.  Intravenous barbiturates, anticonvulsant agents, or muscle relaxants should only be administered by those familiar with their use.  Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated.  Supportive treatment of circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may require administration of intravenous fluids, and, when appropriate, a vasopressor dictated by the clinical situation (such as ephedrine or epinephrine to enhance myocardial contractile force).</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> due to sympathetic relaxation may be managed by giving intravenous fluids (such as isotonic saline solution or Lactated Ringer’s Injection), in an attempt to relieve mechanical obstruction of venous return, or by using vasopressors (such as ephedrine which increases the force of myocardial contractions) and, if indicated, by giving plasma expanders or whole blood.</p>
<p>Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated after initial administration of oxygen by mask if difficulty is encountered in the maintenance of a patent airway, or if prolonged ventilatory support (assisted or controlled) is indicated.</p>
<p>Recent clinical data from patients experiencing local anesthetic-induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> demonstrated rapid development of <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>, and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> with bupivacaine within a minute of the onset of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.  These observations suggest that oxygen consumption and <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> production are greatly increased during local anesthetic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and emphasize the importance of immediate and effective ventilation with oxygen which may avoid <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p>If not treated immediately, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> with simultaneous <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>, and <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> plus myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> from the direct effects of the local anesthetic may result in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>, or <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.  Respiratory abnormalities, including <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, may occur.  Underventilation or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to a high or total spinal may produce these same signs and also lead to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> if ventilatory support is not instituted.  If <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> should occur, standard cardiopulmonary resuscitative measures should be instituted and maintained for a prolonged period if necessary.  Recovery has been reported after prolonged resuscitative efforts.</p>
<p>The supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus.  Therefore during treatment of systemic toxicity, maternal <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span> following regional block, the parturient should be maintained in the left lateral <span class="product-label-link" type="condition" conceptid="4127794" conceptname="Decubitus">decubitus</span> position if possible, or manual displacement of the uterus off the great vessels be accomplished.</p>
<p>The mean <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL.  The intravenous and subcutaneous LD<span class="Sub">50</span> in mice is 6 mg/kg to 8 mg/kg and 38 mg/kg to 54 mg/kg, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ead0e7c4-647a-4c73-9817-e8c6e42f07dd"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient.  The smallest dose and concentration required to produce the desired result should be administered.  Dosages of Sensorcaine-MPF Spinal Injection should be reduced for elderly and debilitated patients and patients with cardiac and/or liver disease.</p>
<p>For specific techniques and procedures, refer to standard textbooks.</p>
<p>There have been adverse event reports of <span class="product-label-link" type="condition" conceptid="4345581" conceptname="Chondrolysis of articular cartilage">chondrolysis</span> in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures.  Sensorcaine is not approved for this use (see <span class="Bold"><span class="Emphasis"><a href="#ab7133f3-25eb-47e8-97ad-63cfdc5f837b">WARNINGS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#ead0e7c4-647a-4c73-9817-e8c6e42f07dd">DOSAGE AND ADMINISTRATION</a></span></span>). </p>
<p>The extent and degree of spinal anesthesia depend upon several factors including dosage, specific gravity of the anesthetic solution, volume of solution used, force of injection, level of puncture, and position of the patient during and immediately after injection.</p>
<p>Seven and one-half mg (7.5 mg or 1 mL) Sensorcaine-MPF Spinal Injection has generally proven satisfactory for spinal anesthesia for lower extremity and perineal procedures including TURP and vaginal hysterectomy.  Twelve mg (12 mg or 1.6 mL) has been used for lower abdominal procedures such as abdominal hysterectomy, tubal ligation, and appendectomy.  These doses are recommended as a guide for use in the average adult and may be reduced for the elderly or debilitated patients. Because experience with Sensorcaine-MPF Spinal Injection is limited in patients below the age of 18 years, dosage recommendations in this age group cannot be made.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="b13d0ab2-3340-489e-9431-fbdee08fd41f"></a><a name="section-10.1"></a><p></p>
<h2>Obstetrical Use</h2>
<p class="First">Doses as low as 6 mg of bupivacaine hydrochloride have been used for vaginal delivery under spinal anesthesia.  The dose range of 7.5 mg to 10.5 mg (1 mL to 1.4 mL) bupivacaine hydrochloride has been used for Cesarean section under spinal anesthesia.</p>
<p>In recommended doses, Sensorcaine-MPF Spinal Injection produces complete motor and sensory block.</p>
<p>Unused portions of solutions should be discarded following initial use.</p>
<p>Sensorcaine-MPF Spinal Injection should be inspected visually for discoloration and particulate matter prior to administration; solutions which are discolored or which contain particulate matter should not be administered.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="a0d29319-72b7-4da6-9a31-37163344e2e5"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Sensorcaine-MPF Spinal Injection is available as follows:</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">              Product            </span></span></p>
<p><span class="Bold"><span class="Emphasis">               No.            </span></span></p>
<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">              NDC            </span></span></p>
<p><span class="Bold"><span class="Emphasis">               No.            </span></span></p>
<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<br><p class="First"><span class="Bold"><span class="Emphasis">              Strength            </span></span></p>
<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<br><p class="First"><span class="Bold"><span class="Emphasis">              Size            </span></span></p>
<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">470302    </p>
<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">63323-473-02    </p>
<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">Bupivacaine HCl </p>
<p>0.75% in dextrose    </p>
<p>8.25% injection.     </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">2 mL ampules packaged </p>
<p>in tens.</p>
<br>
</td>
</tr>
</tbody></table>
<p>Store at 20° to 25°C (68° to 77°F) [see USP                             Controlled Room Temperature].</p>
<p><span class="Bold"><span class="Emphasis">      Sensorcaine-MPF Spinal Injection                                     solution may be autoclaved once at 15 pound pressure,                                     121°C (250°F) for 15 minutes.  Do not                                     administer any solution which is discolored or contains                                     particulate matter.    </span></span></p>
<p>SENSORCAINE is a trademark of Fresenius Kabi USA, LLC.</p>
<p>Manufactured for:</p>
<p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab7d1ab1-3d58-4562-a3be-c8b2b12e99cf&amp;name=sensorcaine-spinal-figure-3-fklogo.jpg"> </p>
<p>Made in Austria</p>
<p>451108D/Revised: November 2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ca5cf105-a920-46e9-906e-bdb10acb9db1"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis"> PACKAGE LABEL - PRINCIPAL DISPLAY - Sensorcaine Spinal 2 mL Ampule </span></span> </p>
<p><span class="Bold"><span class="Emphasis"> NDC </span></span> 63323-473-02</p>
<p>470302</p>
<p><span class="Bold"><span class="Emphasis"> Sensorcaine<span class="Sup">®</span>-MPF </span></span></p>
<p><span class="Bold"><span class="Emphasis"> (bupivacaine HCl in dextrose injection, USP) </span></span></p>
<p><span class="Bold"><span class="Emphasis">SPINAL</span></span>  <span class="Bold"><span class="Emphasis">2 mL</span></span> ampule</p>
<p>bupivacaine HCl 0.75% in dextrose 8.25% injection</p>
<p> Methylparaben Free </p>
<p> </p>
<p><img alt="470302-ampule" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab7d1ab1-3d58-4562-a3be-c8b2b12e99cf&amp;name=sensorcaine-spinal-figure-4-470302-ampule.jpg"><br>
 </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL                                     DISPLAY - Sensorcaine 2 mL Ampule Carton Panel</span></span> </p>
<p><span class="Bold"><span class="Emphasis">      NDC    </span></span> 63323-473-02</p>
<p>470302</p>
<p><span class="Bold"><span class="Emphasis">          Sensorcaine<span class="Sup">®</span>-MPF        </span></span></p>
<p><span class="Bold"><span class="Emphasis">      (bupivacaine HCl in                                             dextrose injection, USP)                                             </span></span></p>
<p>SPINAL</p>
<br><p><img alt="470302-carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ab7d1ab1-3d58-4562-a3be-c8b2b12e99cf&amp;name=sensorcaine-spinal-figure-5-470302-carton.jpg"> </p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SENSORCAINE 		
					MPF</strong><br><span class="contentTableReg">bupivacaine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-473</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBARACHNOID</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUPIVACAINE HYDROCHLORIDE</strong> (BUPIVACAINE) </td>
<td class="formItem">BUPIVACAINE HYDROCHLORIDE ANHYDROUS</td>
<td class="formItem">7.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DEXTROSE</strong></td>
<td class="formItem">82.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-473-02</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071202</td>
<td class="formItem">05/25/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi Austria GmbH</td>
<td class="formItem"></td>
<td class="formItem">300206604</td>
<td class="formItem">MANUFACTURE(63323-473)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>003494b8-9599-47be-b4b1-5fab2d4434fa</div>
<div>Set id: ab7d1ab1-3d58-4562-a3be-c8b2b12e99cf</div>
<div>Version: 3</div>
<div>Effective Time: 20141110</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
